Poloxamer 188
- Generic Name
- Poloxamer 188
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 691397-13-4
- Unique Ingredient Identifier
- LQA7B6G8JG
- Background
Poloxamer 188 (P188) is a nonionic block linear copolymer that exhibits rheologic, anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models . Composed of two hydrophilic side-chains attached to a hydrophobic center core , its average molecular weight is 8400 Daltons. P188 was originally approved by the FDA in the 1960...
- Indication
Indicated to reduce viscosity in the blood before transfusions.
- Associated Conditions
- -
- Associated Therapies
- -
Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02646358
- Locations
- 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
Evaluation of Vepoloxamer in Chronic Heart Failure
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02596477
- Locations
- 🇦🇺
Research Center, Melbourne, Victoria, Australia
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00004408
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath